Mutations of FLT3 in AML is an entity characterized by a significant poor prognosis and are described in about 30% of AML in adults. Usually patients with this subtype of AML carrying either internal tandem duplication (ITD) or mutation at codon 835 are referred for allogeneic stem cell transplantation (ASCT) but a proportion of them would eventually relapse. The introduction of targeted therapy against FLT3 + AML is yielding conflicting results and many trials are running with new molecules. We used sorafenib, a multi-targeted tyrosine kinase inhibitor FDA approved for the treatment of advanced renal cell and hepatocellular carcinoma, on a compassionate basis in two patients with FLT3 + AML relapsing after ASCT.
Sora', F., Chiusolo, P., Metafuni, E., Bellesi, S., Giammarco, S., Laurenti, L., Ausoni, G., Zini Tanzi, G., Bajer, J. A., Balducci, M., Leone, G., Sica, S., Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation., <<LEUKEMIA RESEARCH>>, 2011; 35 (3): 422-423. [doi:10.1016/j.leukres.2010.10.025] [http://hdl.handle.net/10807/62678]
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
Sora', Federica;Chiusolo, Patrizia;Metafuni, Elisabetta;Bellesi, Silvia;Giammarco, Sabrina;Laurenti, Luca;Ausoni, Giuseppe;Zini Tanzi, Gina;Bajer, Jolanta Alina;Balducci, Mario;Leone, Giuseppe;Sica, Simona
2011
Abstract
Mutations of FLT3 in AML is an entity characterized by a significant poor prognosis and are described in about 30% of AML in adults. Usually patients with this subtype of AML carrying either internal tandem duplication (ITD) or mutation at codon 835 are referred for allogeneic stem cell transplantation (ASCT) but a proportion of them would eventually relapse. The introduction of targeted therapy against FLT3 + AML is yielding conflicting results and many trials are running with new molecules. We used sorafenib, a multi-targeted tyrosine kinase inhibitor FDA approved for the treatment of advanced renal cell and hepatocellular carcinoma, on a compassionate basis in two patients with FLT3 + AML relapsing after ASCT.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
